Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBruising at or near the injection site is a recognised, documented side effect of Wegovy (semaglutide). It appears in the medicine's prescribing information and has been reported in clinical trials — most occurrences are minor, settle without treatment, and are not a sign that anything has gone seriously wrong. That said, it is worth understanding why bruising happens, how to reduce it, and when a bruise after a Wegovy shot warrants a call to your prescriber. These are prescription-only medicines assessed and issued by a qualified clinician; any unusual or worsening skin reactions should be discussed with your healthcare team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy SmPC (Summary of Product Characteristics, accessible via the electronic Medicines Compendium) lists injection-site bruising among the local reactions reported during clinical development. In the landmark STEP 1 trial (68 weeks, around 1,900 adults with obesity, comparing 2.4 mg semaglutide against placebo) injection-site reactions as a category were more common in the semaglutide group than in the placebo group, consistent with any subcutaneous injection programme. The NHS medicines page for semaglutide confirms injection-site bruising as a common side effect, placing it alongside redness, itching and swelling in the skin reactions category. 'Common' in medicines language means it affects roughly 1 in 10 to 1 in 100 people, so not universal, but not rare either. The bruise forms when the needle tip grazes a small blood vessel just beneath the skin surface, allowing a small amount of blood to pool in the surrounding tissue. This is inherent to any subcutaneous injection and is not unique to semaglutide. If you are wondering whether semaglutide could be making you bruise more easily across your whole body, the evidence suggests the medicine itself does not appear to alter clotting factors or platelet function in a way that would cause that. The bruising, when it occurs, is local.
Several practical factors influence whether a particular injection produces a bruise. Pressing the pen firmly enough against the skin, holding it at the correct angle, and injecting steadily rather than rushing all reduce trauma to nearby capillaries. Cold medication straight from the fridge can cause more discomfort and tissue irritation, so letting the pen sit at room temperature for a short while before use is commonly suggested, check the Patient Information Leaflet for the exact window your pen allows. Site rotation matters too: returning to the same small patch of skin repeatedly means injecting into tissue that is already a little tender and potentially more vascular. The licensed injection sites are the abdomen, the front of the thigh, and the upper arm; moving between these and varying the exact spot within each area each week gives tissues time to recover. If you are on anticoagulants, aspirin or certain anti-inflammatory medicines, bruising may be more noticeable, tell your prescriber about everything you take regularly. There is also simple biological variation: some people bruise more visibly than others regardless of technique, because skin thickness, subcutaneous fat depth and capillary fragility differ between individuals. That does not mean anything is wrong. Our guide to bruising after a Wegovy shot covers the practical steps in more detail.
A small, contained bruise appearing within 24 hours of an injection, sitting directly at or just beside the injection site, and fading over three to five days: that is the typical pattern, and it does not need medical review. Applying light pressure with a clean tissue immediately after injecting (without rubbing) can limit the spread. A cold compress in the first hour may also help reduce discolouration. Where things look different is worth noting. A bruise that continues to grow after the first day, one that becomes hot, swollen or increasingly painful, or one accompanied by any redness spreading outward could indicate a local infection and should be assessed. Similarly, if you begin noticing bruises appearing on parts of your body where you have not injected, or bruises that are unusually large or take longer than two weeks to resolve, those patterns are not explained by the injection itself and deserve a proper clinical review. The MHRA Yellow Card scheme exists for reporting suspected side effects of any medicine, including unexpected bruising or skin reactions, you can submit a report yourself or ask your prescriber to do so. For comparison of how the bruising profile of semaglutide compares with other injectable treatments, this page on semaglutide bruising goes into further detail on the broader injectable GLP-1 picture. For questions about cost or what is included when you take treatment through a regulated service, the Wegovy pricing page explains what a private prescription covers.
The good news is that bruising from semaglutide injections tends to become less frequent as experience with the pen builds. First-time injectors, or people returning after a break in treatment, often report more noticeable injection-site reactions in the early weeks. Technique improves quickly. A few things make a consistent difference: warming the pen slightly before use, choosing a fresh site each week rather than defaulting to the same spot, releasing the skin fold gently rather than pinching hard, and not rubbing the area afterwards. If bruises are appearing more often than feels acceptable, or if the discomfort is putting you off injecting consistently, that is exactly the kind of thing worth raising with your prescriber rather than quietly adjusting your own dose timing. Consistency matters for how well the treatment works, so anything that affects your confidence with the pen is clinically relevant. Patients sometimes delay their injection until a bruise from the previous week has fully cleared, understandably, but it is worth checking with your clinical team whether that timing shift is appropriate rather than assuming it is fine. And on that note: if a bank holiday, a holiday abroad, or even a busy Monday falls on your usual injection day, speaking to your prescriber in advance about timing is always the right call. You can read more about bruising patterns on Wegovy and how other people manage them, or explore the full Wegovy treatment overview for context on the wider side-effect profile. If you have questions about starting treatment or switching from another medicine, speaking to our prescribers is a straightforward first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.